Research
Hormonal
Younger men (≤44 years) and older women (≥65 years) represent the highest-risk subgroups for uncontrolled diabetes, exhibiting significantly worse glycemic and lipid profiles compared to other demographic groups.
If you are a man under 45 with diabetes, your risk for uncontrolled blood sugar and lipids is significantly higher than older patients. Do not assume youth protects you from complications; prioritize strict metabolic control to prevent long-term disability.
GoodQualifiesHIGH confidence
younger men ≤44 years old (uncontrolled FPG, 2hPPG, A1C, triglycerides, total cholesterol, and LDL-C) and older women ≥65 years old (2hPPG and A1C) represent the two high-risk groups of patients with diabetes in Iran.
Why this rating
Large sample size allows for robust subgroup analysis.
Source
Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016)
Alireza Esteghamati et al. · Scientific Reports · 2017
DOI 10.1038/s41598-017-13379-z
cohort · n=30202Cited 324×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In tertiary-care diabetic populations, comprehensive management of glycemic, lipid, and blood pressure targets (ABC control) remains suboptimal, with only 20.2% of patients achieving all preset control goals despite high medication availability.Good
- Chronic vascular complications, including retinopathy, nephropathy, neuropathy, and ischemic heart disease, are highly prevalent in diabetic populations, with over half of patients exhibiting at least one complication.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →